List of PFAS Concerns from January 10, 2018 SAB meeting

This draft document lists concerns documented on the whiteboard at the January 10, 2018 SAB meeting; references have been added from meeting notes and materials, and have been distributed for Board review. This draft includes updates from Board members as of 2/8/18. The Board notes that the weight of evidence varies among endpoints.

PFBA

Persistence (reviewed in Danish EPA 2015b)

Very mobile (potential global transport) (Cai 2012, NICNAS 2016a)

Thyroid effects (Bjork and Wallace 2009, MN DPH 2011a)

Liver effects (Foreman 2009, Bjork and Wallace 2009, MN DPH 2011a, Wolf 2008, Rosenmai 2016)

Endocrine effects (Foreman 2009)

Hematological effects (MN 2011a, Butenhoff 2012a, van Otterdijk 2007b)

Developmental effects (Das 2008)

Corrosivity (HAZMAP)

Phytoaccumulation (Blaine 2014)

Presence in serum (*Nilsson 2013*), breastmilk (*Lorenzo 2016*). Toxicokinetics: human half-life 72-87 hrs (*Chang 2008*)

Presence in the environment (Su 2016, ATSDR 2008)/ongoing exposure

PFBS

Asthma (Dong 2013)

Immunotoxicity (Corsini 2012)

Persistence (reviewed in Danish EPA 2015b)

Very mobile (potential global transport)(Zhao 2012) (reviewed in Danish EPA 2015b)

Thyroid effects (Feng 2017)

Metabolic effects

Endocrine effects (Gorrochategui 2014)

Hematological effects (Lieder 2009b, MN DPH 2011)

Developmental effects (Feng 2017, Lieder 2009a, Lieder 2009b)

Corrosivity (HSDB 2017b)

Bioaccumulation - marine (Chu 2016, precursor FBSA in fish), earthworm (Zhao 2013)

Presence in the environment (Chu 2016), human serum (Glynn 2012, Glynn 2012a, Gyllenhammar 2015), ongoing exposure

Neurotoxicity (Slotkin 2008)

Kidney effects (Lieder 2009a, Lieder 2009b, MN DPH 2011)

PFHxA

Persistence (reviewed in Danish EPA 2015 and ENVRION 2014)

Very mobile (potential global transport) (reviewed in Danish EPA 2015)

Thyroid effects (Ren 2016)

Liver effects (high dose) (Loveless 2009)

Endocrine effects (PPARα Wolf 2008, Rosenmai 2016)

Developmental effects (ToxServices 2016 - Greenscreen: moderate [Loveless 2009], Iwai 2014)

Corrosivity (ECHA)

Presence in serum (*Russell 2013, Guo 2011*), breastmilk (*Kang 2016*). Toxicokinetics: exposed workers serum half-life 14-49 days (*Russell 2013*)

Presence in the environment (Campo 2016, Gyllenhammar 2015, MI DCH 2015)/ongoing exposure

Neurotoxicity (Loveless 2009, Klaunia 2015)

Kidney effects (NICNAS 2017)

Bioaccumulation: earthworm (Zhao 2013)

Eco toxicity: Bluegreen algae (HSDB/Latala 2009), zebrafish embryo amplified PFOS/PCB mixture toxicity (Blanc 2017)

PFHxS

Persistence (reviewed in ECHA 2017)

Thyroid effects (Jain 2013, Weiss 2009)

Liver/metabolic effects (Butenhoff 2009)

Endocrine effects (PPARa: Das 2017, Rosenmai 2017)

Hematological effects

Neurodevelopmental effects (Maisonet 2012, Joensen 2009, Viberg 2013, Lee and Viberg 2013, Lee and Yang 2016)

Corrosivity (ECHA)

Bioaccumulation (Haukas 2007, Houde 2006, Butt 2008, reviewed in ECHA 2017) earthworm (Rich 2014)

Presence in serum (Olsen 2007, Gyllenhammar 2015, Bartolome 2017), breastmilk (Tao 2008, Karrman 2010, Sundstrom 2011). Toxicokinetics: long half-life (7-8 yrs) in human serum (Olsen 2007)

Widespread presence in the environment, including remote regions/ongoing exposure (*Zhou 2014, Houde 2006, Butt 2008, Campo 2016, Kelly 2009a, reviewed in ECHA 2017*)

Neurotoxicity (Zhang 2016, Lee and Yang 2014, Viberg 2013)

Asthma (Dong 2013)